Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||Carboplatin + Paclitaxel + Ramucirumab||Phase II||Actionable||In a Phase II study, preliminary results reported a 67% response rate in NSCLC patients treated with Cyramza (ramucirumab) in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) (PMID: 22481432).||22481432|